Evidence map›Paper›PMID 40978497›Full record

ArticleJournal of translational autoimmunity2025

Splicing-based biomarkers define a robust multigene classifier for relapsing-remitting multiple sclerosis.

Federica Airi, Valeria Rimoldi, Elvezia Maria Paraboschi, Valentina Pellicanò, Damiano Verda, Giuseppe Liberatore, Claudia Cantoni, Laura Piccio, Alvino Bisecco, Anita Capalbo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational autoimmunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Federica AiriDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.
Valeria RimoldiDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.
Elvezia Maria ParaboschiDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.
Valentina PellicanòDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.
Damiano VerdaRulex Innovation Labs, Via Felice Romani 9, 16122 Genova, Italy.
Giuseppe LiberatoreNeuromuscular and Neuroimmunology Service, IRCCS Humanitas Research Hospital, Italy.
Claudia CantoniDepartment of Translational Neuroscience, Barrow Neurological Institute, Phoenix, USA.
Laura PiccioNeuroscience theme, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
Alvino BiseccoDepartment of Advanced Medical and Surgical Sciences - University of Campania "Luigi Vanvitelli", Naples, Italy.
Anita CapalboDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.
Giulia CardamoneDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.
Eduardo Nobile-OrazioNeuromuscular and Neuroimmunology Service, IRCCS Humanitas Research Hospital And Milan University, Italy.
Giulia SoldàDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.
Rosanna AsseltaDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alternative splicing (AS) is recognized as a key mechanism in multiple sclerosis (MS). We aimed to construct and validate a multivariate AS-based classifier (MS-Splicing Score, MS-SS) for the discrimination of relapsing-remitting MS (RRMS) patients from healthy controls. Methods: Three AS events ( Results: The MS-SS distinguished RRMS patients from controls in both cohorts (Italy: p = 0.00083, AUC = 0.71, 95 %CI = 0.59-0.82; USA: p = 0.00074, AUC = 0.77, 95 %CI = 0.63-0.90). In the pooled dataset, the score remained significantly elevated in MS (p = 5.9 × 10 Conclusion: Our study introduces a novel, robust AS-based classifier for RRMS and proposes a strategy for transcriptome-based biomarker development in neuroimmunology. However, the relatively small sample sizes within each cohort may limit the generalizability of these findings, warranting larger validation studies to confirm the clinical utility of this biomarker.

Indexed as

Alternative splicingBiomarkersMultiple sclerosisPeripheral bloodSplicing score

Identifiers

PMID40978497
PMCPMC12448017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.